3,6,19-Trihydroxy-23-oxo-12-ursen-28-oic acidCAS# 131984-82-2 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 131984-82-2 | SDF | Download SDF |
PubChem ID | 21672641 | Appearance | Powder |
Formula | C30H46O6 | M.Wt | 502.7 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (1R,2R,4aS,6aR,6aS,6bR,8R,8aR,9S,10S,12aR,14bS)-9-formyl-1,8,10-trihydroxy-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid | ||
SMILES | CC1CCC2(CCC3(C(=CCC4C3(CC(C5C4(CCC(C5(C)C=O)O)C)O)C)C2C1(C)O)C)C(=O)O | ||
Standard InChIKey | NBJMEEGTJUXGLI-UHVFENMYSA-N | ||
Standard InChI | InChI=1S/C30H46O6/c1-17-9-12-30(24(34)35)14-13-27(4)18(22(30)29(17,6)36)7-8-20-25(2)11-10-21(33)26(3,16-31)23(25)19(32)15-28(20,27)5/h7,16-17,19-23,32-33,36H,8-15H2,1-6H3,(H,34,35)/t17-,19-,20-,21+,22-,23-,25-,26-,27-,28-,29-,30+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
3,6,19-Trihydroxy-23-oxo-12-ursen-28-oic acid Dilution Calculator
3,6,19-Trihydroxy-23-oxo-12-ursen-28-oic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9893 mL | 9.9463 mL | 19.8926 mL | 39.7852 mL | 49.7315 mL |
5 mM | 0.3979 mL | 1.9893 mL | 3.9785 mL | 7.957 mL | 9.9463 mL |
10 mM | 0.1989 mL | 0.9946 mL | 1.9893 mL | 3.9785 mL | 4.9731 mL |
50 mM | 0.0398 mL | 0.1989 mL | 0.3979 mL | 0.7957 mL | 0.9946 mL |
100 mM | 0.0199 mL | 0.0995 mL | 0.1989 mL | 0.3979 mL | 0.4973 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- CC0651
Catalog No.:BCC4200
CAS No.:1319207-44-7
- 1,3,6,8-tetrahydroxy-4-(3-methyl-2-buten-1-yl)-9H-Xanthen-9-one
Catalog No.:BCN1585
CAS No.:1319198-98-5
- Paricalcitol
Catalog No.:BCC1839
CAS No.:131918-61-1
- Solanesol
Catalog No.:BCN2596
CAS No.:13190-97-1
- Goitrin
Catalog No.:BCN2764
CAS No.:13190-34-6
- Fudosteine
Catalog No.:BCC4661
CAS No.:13189-98-5
- 2-Hydroxyethyl Salicylate
Catalog No.:BCN3579
CAS No.:87-28-5
- (3R)-(+)-1-Benzyl-3-(tert-butoxycarbonylamino)pyrrolidine
Catalog No.:BCC8389
CAS No.:131878-23-4
- Lexacalcitol
Catalog No.:BCC1704
CAS No.:131875-08-6
- (R,R)-2,6-Bis(4-isopropyl-2-oxazolin-2-yl)pyridine
Catalog No.:BCC8396
CAS No.:131864-67-0
- Aphagranin A
Catalog No.:BCN6889
CAS No.:1318173-53-3
- Cardenolide B-1
Catalog No.:BCN4714
CAS No.:1318158-89-2
- Shizukaol A
Catalog No.:BCN6984
CAS No.:131984-98-0
- Benztropine mesylate
Catalog No.:BCC4524
CAS No.:132-17-2
- Diphenylpyraline HCl
Catalog No.:BCC3768
CAS No.:132-18-3
- Pheniramine Maleate
Catalog No.:BCC4700
CAS No.:132-20-7
- Benzydamine HCl
Catalog No.:BCC4637
CAS No.:132-69-4
- Dihydrocucurbitacin B
Catalog No.:BCN3118
CAS No.:13201-14-4
- UNC 0646
Catalog No.:BCC2431
CAS No.:1320288-17-2
- UNC 0631
Catalog No.:BCC4143
CAS No.:1320288-19-4
- Cryptoacetalide
Catalog No.:BCN3139
CAS No.:132059-23-5
- Marmesin angelate
Catalog No.:BCN8139
CAS No.:13209-79-5
- Ropivacaine hydrochloride monohydrate
Catalog No.:BCC5169
CAS No.:132112-35-7
- O,O-diacetyldaurisoline
Catalog No.:BCC8221
CAS No.:132139-17-4
Breastmilk with a high omega-6 to omega-3 fatty acid ratio induced cellular events similar to insulin resistance and obesity in 3T3-L1 adipocytes.[Pubmed:28335075]
Pediatr Obes. 2018 May;13(5):285-291.
BACKGROUND: An imbalance of omega (n)-3 and n-6 polyunsaturated fatty acids (PUFA) during critical periods of development may have adverse effects on the health of the newborn in later life. OBJECTIVES: We hypothesized that breastmilk with higher n-6 to n-3 PUFA ratio will have higher inflammatory cytokines and initiate cellular events similar to insulin resistance and obesity. METHODS: Breastmilk was collected from healthy women who gave natural birth at full term. Breastmilk fatty acids were measured using gas chromatography; samples were pooled based on the n-6 to n-3 PUFA ratio (high, medium and low), and soluble cytokines were measured. Pooled samples were used to treat 3T3-L1 cells; mRNA expression of diacylglycerol acyltransferase2, stearoyl-CoA desaturase-1, leptin and RPLPO was measured. RESULTS: Breastmilk with a higher ratio of n-6 to n-3 PUFA showed higher pro-inflammatory cytokines; there was a direct correlation between n-6 PUFA and pro-inflammatory cytokines. Breastmilk with a higher ratio of n-6 to n-3 PUFA increased the expression of genes involved in lipogenesis. CONCLUSIONS: Pro-inflammatory cytokines in breastmilk are associated with higher levels of n-6 PUFA in breastmilk and has the capacity to alter adipose tissue metabolism to likely predispose the newborn to a higher risk of obesity in later life.
Design, Synthesis and Molecular Docking of 1-Cyclopropyl-6- Fluoro-4-Oxo-7-{4-[2-(4-Substituted-Phenyl)-2-(Substituted)-Ethyl] -1-Piperazinyl}-1,4-Dihydroquinoline-3-Carboxylic Acid as an Antimicrobial Agents.[Pubmed:28240185]
Curr Drug Discov Technol. 2017;14(4):255-269.
BACKGROUND: Quinolone scaffolds are widely used for the synthesis of a number of medicinal compounds with variety of biological activity. In view of the reported antimicrobial activity of various fluoroquinolones, the structure activity studies of various substituted quinolones, which proved the importance of the C-7 substituents to exhibit potent antimicrobial activities. OBJECTIVE: Based on the structural activity relationship at C-7 position it was rationalized to design and synthesize new quinolone derivatives with increasing bulk at C-7 position of the main 6-fluoroquinolone scaffold. METHODS: A novel series of 1-cyclopropyl-6-fluoro-4-oxo-7-{4-[2-(4-substituted-phenyl)- 2-(substituted)-ethyl]-1-piperazinyl}-1,4-dihydroquinoline-3-carboxylic acid derivatives were synthesized by reacting 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4- dihydroquinoline-3-carboxylic acid with 2-bromo-4-(substituted) acetophenone in the presence of sodium bicarbonate to obtain 1-cyclopropyl-6-fluoro-7-{4-[2-(4- substitutedphenyl)-2-oxoethyl]-1-piperazinyl}-4-oxo-1,4-dihydroquinoline-3-carbox ylic acids 2a-2d. Compound 2a-2d underwent further reaction with different substituted hydrazide, hydroxylamine hydrochloride or methoxylamine in glacial acetic acid to give 3a-7d. In vitro antibacterial activity of the synthesized compounds 3a-7d was studied and the MIC value was determined by the broth dilution method. RESULT: Among all the synthesized compounds 3a-7d some compounds showed antimicrobial activity in comparison to the reference standard ciprofloxacin. CONCLUSION: The compound 6d showed the reasonable good antibacterial activity among all the tested compounds. To understand antibacterial data on structural basis and the interaction of binding sites with bacterial protein receptor, the docking studies were carried out using topoisomerase II DNA gyrase enzymes (PDB ID. 2XCT) by shrodinger's maestro program.
Low dietary n-6/n-3 polyunsaturated fatty acid ratio prevents induced oral carcinoma in a hamster pouch model.[Pubmed:28292553]
Prostaglandins Leukot Essent Fatty Acids. 2018 Sep;136:67-75.
Dietary fatty acid patterns have been linked to the prevalence of certain cancers, however in oral carcinoma is limited. Thus, we investigated the chemopreventive effects of various dietary n-6 and n-3 fatty acids in a 9,10-dimethyl-1,2-benz[a]-anthracene (DMBA)- and betel quid extract (BQE) -induced hamster oral cancer model. Thirty 6-week-old adult male hamsters were housed and divided into normal, low, and high dietary n-6 and n-3 fatty acid groups under DMBA + BQE treatment for 16 weeks. The right buccal pouch of all hamsters were evaluated by tumor number, volume, burden and selected inflammatory parameters. The results indicate that the low dietary n-6/n-3 fatty acid group exhibited a significantly lower tumor number, volume, and burden than those of the other groups. Furthermore, this group had significantly lower nuclear factor-kappaB, proliferating cell nuclear antigen, and cyclin D1 expression in the right buccal pouch tissue. In conclusion, the lower dietary n-6/n-3 fatty acid ratio exerted chemopreventive effects in the DMBA- and BQE-induced hamster oral cancer model.
Discovery of 4-((3'R,4'S,5'R)-6''-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2''-oxodispiro[ cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamido)bicyclo[2.2.2]octane -1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development.[Pubmed:28339198]
J Med Chem. 2017 Apr 13;60(7):2819-2839.
We previously reported the design of spirooxindoles with two identical substituents at the carbon-2 of the pyrrolidine core as potent MDM2 inhibitors. In this paper we describe an extensive structure-activity relationship study of this class of MDM2 inhibitors, which led to the discovery of 60 (AA-115/APG-115). Compound 60 has a very high affinity to MDM2 (Ki < 1 nM), potent cellular activity, and an excellent oral pharmacokinetic profile. Compound 60 is capable of achieving complete and long-lasting tumor regression in vivo and is currently in phase I clinical trials for cancer treatment.